# Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)

> **NCT03443869** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 601 (actual)

## Conditions studied

- CMV Disease

## Interventions

- **DRUG:** Letermovir
- **DRUG:** Valganciclovir
- **DRUG:** Acyclovir (ACV)
- **DRUG:** Placebo to ACV
- **DRUG:** Placebo to LET
- **DRUG:** Placebo to VGCV

## Key facts

- **NCT ID:** NCT03443869
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-03
- **Primary completion:** 2022-04-05
- **Final completion:** 2022-04-05
- **Target enrollment:** 601 (ACTUAL)
- **Last updated:** 2023-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03443869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03443869, "Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03443869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*